| Existing Vaccines |
Dosage |
Advantages |
Drawbacks |
Hib - Haemophilus b
Conjugate Vaccine
(Tetanus Toxoid Conjugate)
ActHIB® - Sanofi-Pasteur |
1 dose of 0.5ml contains 10 μg purified polysaccharide, 3 doses with 6 to 8 weeks of interval. (Intramuscular) |
Can be used in children as young as 2 months old - achieve high peak antibody concentration |
Only protects against type b, and does not offer coverage to emerging non-capsulated groups [11,33] |
Haemophilus b conjugate Vaccine
(Diphtheria CRM197 Protein Conjugate)
HibTITER®- Wyeth Lederle |
1 dose contains10 μg of purified Haemophilus b saccharide and 25 μg of CRM197 protein. 3 doses with 2 months interval. (Intramuscular) |
Achieve high peak antibody concentration, offer long term protection. |
Only protects against type b, and does not offer coverage to emerging non-capsulated groups [11]. |
Liquid PedvaxHIB®
[Haemophilus b Conjugate Vaccine
(Meningococcal Protein Conjugate)]- Merk |
1 dose contains7.5 μg of Haemophilus b PRP (polysaccharide capsule), 125 μ of
N. meningitidisOMPC and 225 μg of aluminum (Intramuscular) |
Provides the
earliest antibody levels thought to be protective against invasive
disease. |
Only protects against type b, and does not offer coverage to emerging non-capsulated groups. Does not achieve high peak antibody concentration as the other two vaccines [11,34]. |
